Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 3 (2006), Issue 4 (April)

1. Four-dimensional proton treatment planning for lung tumors.
   Int J Radiat Oncol Biol Phys, 64(5): 1589-95. [Abstract] [Full-text]
2. Enhanced radiosensitization of p53 mutant cells by oleamide.
   Int J Radiat Oncol Biol Phys, 64(5): 1466-74. [Abstract] [Full-text]
3. A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
   Am J Clin Oncol, 29(2): 143-7. [Abstract] [Full-text]
4. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review.
   J Clin Oncol, 24(11): 1761-9. [Abstract] [Full-text]
5. Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer.
   J Clin Oncol, 24(11): 1729-44. [Abstract] [Full-text]
6. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.
   J Clin Oncol, 24(11): 1679-88. [Abstract] [Full-text]
7. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers.
   J Clin Oncol, 24(11): 1672-8. [Abstract] [Full-text]
8. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
   J Clin Oncol, 24(11): 1689-99. [Abstract] [Full-text]
9. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
   J Clin Oncol, 24(11): 1700-4. [Abstract] [Full-text]
10. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.
    Cancer Chemother Pharmacol, 57(6): 755-60. [Abstract] [Full-text]
11. Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
    Cancer Chemother Pharmacol, 57(6): 796-800. [Abstract] [Full-text]
12. World Health Organization's International Radon Project.
    J Toxicol Environ Health A, 69(7): 759-69. [Abstract] [Full-text]
13. Assessment and management of residential radon health risks: a report from the health Canada radon workshop.
    J Toxicol Environ Health A, 69(7): 735-58. [Abstract] [Full-text]
14. Radon-thoron discriminative measurements in Gansu Province, China, and their implication for dose estimates.
    J Toxicol Environ Health A, 69(7): 723-34. [Abstract] [Full-text]
15. Impact of measurement error in exposures in german radon studies.
    J Toxicol Environ Health A, 69(7): 701-21. [Abstract] [Full-text]
16. Radon epidemiology: continuous and categorical trend estimators when the exposure distribution is skewed and outliers may be present.
    J Toxicol Environ Health A, 69(7): 681-700. [Abstract] [Full-text]
17. Uncertainty analysis of relative biological effectiveness of alpha-radiation for human lung exposure.
    J Toxicol Environ Health A, 69(7): 665-79. [Abstract] [Full-text]
18. Dosimetric challenges for residential radon epidemiology.
    J Toxicol Environ Health A, 69(7): 655-64. [Abstract] [Full-text]
19. Indoor radon and lung cancer risk in connecticut and utah.
    J Toxicol Environ Health A, 69(7): 633-54. [Abstract] [Full-text]
20. An overview of the North American residential radon and lung cancer case-control studies.
    J Toxicol Environ Health A, 69(7): 599-631. [Abstract] [Full-text]
21. A combined analysis of North American case-control studies of residential radon and lung cancer.
    J Toxicol Environ Health A, 69(7): 533-97. [Abstract] [Full-text]
22. Residential radon and lung cancer: end of the story?
    J Toxicol Environ Health A, 69(7): 527-31. [Abstract] [Full-text]
23. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Cancer, 106(8): 1751-8. [Abstract] [Full-text]
24. Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors.
    Int J Radiat Oncol Biol Phys, 65(1): 255-65. [Abstract] [Full-text]
25. Spanish patterns of care for 3D radiotherapy in non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 65(1): 138-42. [Abstract] [Full-text]
26. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters.
    Int J Radiat Oncol Biol Phys, 65(1): 112-24. [Abstract] [Full-text]
27. Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years.
    Int J Radiat Oncol Biol Phys, 65(1): 100-6. [Abstract] [Full-text]
28. Addressing glucose sensitivity measured by F-18 FDG PET in lung cancers for radiation treatment planning and monitoring.
    Int J Radiat Oncol Biol Phys, 65(1): 132-7. [Abstract] [Full-text]
29. High-dose proton beam therapy for Stage I non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 65(1): 107-11. [Abstract] [Full-text]
30. The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis.
    Int J Radiat Oncol Biol Phys, 65(1): 125-31. [Abstract] [Full-text]
31. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
    J Clin Oncol, 24(12): 1807-13. [Abstract] [Full-text]
32. Persisting risk of nickel related lung cancer and nasal cancer among Clydach refiners.
    Occup Environ Med, 63(5): 365-6. [Abstract] [Full-text]
33. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
    J Clin Oncol, 24(12): 1800-6. [Abstract] [Full-text]
34. Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study.
    J Natl Cancer Inst, 98(8): 557-60. [Abstract] [Full-text]
35. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively.
    Oncogene, 25(17): 2452-67. [Abstract] [Full-text]
36. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer.
    Cancer Chemother Pharmacol, 58(1): 86-90. [Abstract] [Full-text]
37. Postoperative chemotherapy in nonsmall cell lung cancer: a systematic review.
    Ann Thorac Surg, 81(5): 1926-36. [Abstract] [Full-text]
38. Therapeutic bronchoscopy interventions before surgical resection of lung cancer.
    Ann Thorac Surg, 81(5): 1839-43. [Abstract] [Full-text]
39. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends.
    Ann Thorac Surg, 81(5): 1830-7. [Abstract] [Full-text]
40. Prevalence of benign disease in patients undergoing resection for suspected lung cancer.
    Ann Thorac Surg, 81(5): 1824-8; discussion 1828-9. [Abstract] [Full-text]
41. Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene.
    Int J Cancer, 119(1): 33-40. [Abstract] [Full-text]
42. Air pollution and risk of lung cancer in a prospective study in Europe.
    Int J Cancer, 119(1): 169-74. [Abstract] [Full-text]
43. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo.
    Int J Cancer, 119(1): 41-8. [Abstract] [Full-text]
44. Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
    Am J Hematol, 81(5): 349-54. [Abstract] [Full-text]
45. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer.
    Biochem Biophys Res Commun, 343(4): 995-1001. [Abstract] [Full-text]
46. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis.
    Cancer, 106(9): 1998-2004. [Abstract] [Full-text]
47. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.
    Oncogene, 25(18): 2628-35. [Abstract] [Full-text]
48. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
    Cancer Chemother Pharmacol, 58(2): 203-9. [Abstract] [Full-text]
49. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons.
    Cancer Chemother Pharmacol, 58(2): 237-44. [Abstract] [Full-text]
50. Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 58(2): 266-71. [Abstract] [Full-text]
51. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Cancer Chemother Pharmacol, 58(2): 256-65. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.